Hemispherx Biopharma and Max Neeman International Team Initiate Influenza Research Programs

Thursday, April 1, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

. . . Clinical Sites Targeted to Enroll Subjects Beginning in Upcoming Monsoon Season

Company/Investor Contact:

Company/Investor Contact:

Dianne Will

Donald Swankie

Hemispherx Biopharma, Inc.

Max Neeman International

518.398.6222

919.424.3345

[email protected]

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store